Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan.

Aiso M, Takikawa H, Tsuji K, Kagawa T, Watanabe M, Tanaka A, Sato K, Sakisaka S, Hiasa Y, Takei Y, Ohira H, Ayada M, Hashimoto E, Kaneko S, Ueno Y, Ohmoto K, Takaki A, Torimura T, Matsuzaki Y, Tajiri K, Yoneda M, Ito T, Kato N, Ikejima K, Mochida S, Yasuda H, Sakamoto N.

Hepatol Res. 2019 Jan;49(1):105-110. doi: 10.1111/hepr.13288.

PMID:
30565816
2.

Synthesis and evaluation of a potent, well-balanced EP2/EP3 dual agonist.

Kinoshita A, Higashino M, Yoshida K, Aratani Y, Kakuuchi A, Hanada K, Takeda H, Naganawa A, Matsuya H, Ohmoto K.

Bioorg Med Chem. 2018 Jan 1;26(1):200-214. doi: 10.1016/j.bmc.2017.11.035. Epub 2017 Nov 24.

PMID:
29203142
3.

Severe Respiratory Event Initially Thought to be Inadvertent Endobronchial Intubation: Possible Complications From Using of a Topical Metered-Dose of 8% Lidocaine Pump Spray.

Arai YC, Kawanishi J, Sakakima Y, Ohmoto K, Ito A, Maruyama Y, Ikemoto T.

Anesth Pain Med. 2016 Apr 16;6(3):e33771. doi: 10.5812/aapm.33771. eCollection 2016 Jun.

4.

The Lateral Position Improved Airway Patency in Anesthetized Patient With Burn-Induced Cervico-Mento-Sternal Scar Contracture.

Arai YC, Kawanishi J, Sakakima Y, Ohmoto K, Ito A, Maruyama Y, Ikemoto T.

Anesth Pain Med. 2016 Mar 5;6(2):e34953. doi: 10.5812/aapm.34953. eCollection 2016 Apr.

5.

Discovery of highly potent dual EP(2) and EP(3) agonists with subtype selectivity.

Kinoshita A, Higashino M, Aratani Y, Kakuuchi A, Matsuya H, Ohmoto K.

Bioorg Med Chem Lett. 2016 Feb 1;26(3):1016-1019. doi: 10.1016/j.bmcl.2015.12.039. Epub 2015 Dec 12.

PMID:
26725951
6.

Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma.

Itadani S, Yashiro K, Aratani Y, Sekiguchi T, Kinoshita A, Moriguchi H, Ohta N, Takahashi S, Ishida A, Tajima Y, Hisaichi K, Ima M, Ueda J, Egashira H, Sekioka T, Kadode M, Yonetomi Y, Nakao T, Inoue A, Nomura H, Kitamine T, Fujita M, Nabe T, Yamaura Y, Matsumura N, Imagawa A, Nakayama Y, Takeuchi J, Ohmoto K.

J Med Chem. 2015 Aug 13;58(15):6093-113. doi: 10.1021/acs.jmedchem.5b00741. Epub 2015 Jul 22.

PMID:
26200813
7.

Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats.

Mitsui K, Niwa T, Kawahara Y, Morimoto N, Ohmoto K, Kato M, Yamaura Y, Yoshimoto N, Suna H, Katsumata S.

Neuropharmacology. 2015 Dec;99:51-66. doi: 10.1016/j.neuropharm.2015.07.011. Epub 2015 Jul 17.

PMID:
26189762
8.

Combination therapy with ONO-KK1-300-01, a cathepsin K inhibitor, and parathyroid hormone results in additive beneficial effect on bone mineral density in ovariectomized rats.

Ochi Y, Yamada H, Mori H, Kawada N, Tanaka M, Imagawa A, Ohmoto K, Kawabata K.

J Bone Miner Metab. 2016 Jan;34(1):33-40. doi: 10.1007/s00774-014-0643-1. Epub 2015 Mar 12.

PMID:
25762435
9.

Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury.

Aihara M, Fujiki H, Mizuguchi H, Hattori K, Ohmoto K, Ishikawa M, Nagano K, Yamamura Y.

J Pharmacol Exp Ther. 2014 May;349(2):258-67. doi: 10.1124/jpet.114.213256. Epub 2014 Feb 25.

PMID:
24570071
10.

ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats.

Ochi Y, Yamada H, Mori H, Kawada N, Kayasuga R, Nakanishi Y, Tanaka M, Imagawa A, Ohmoto K, Kawabata K.

J Bone Miner Metab. 2014 Nov;32(6):645-52. doi: 10.1007/s00774-013-0542-x. Epub 2013 Dec 8.

PMID:
24317478
11.

Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: An analysis of 16 346 treated nodules in 13 283 patients.

Koda M, Murawaki Y, Hirooka Y, Kitamoto M, Ono M, Sakaeda H, Joko K, Sato S, Tamaki K, Yamasaki T, Shibata H, Shimoe T, Matsuda T, Toshikuni N, Fujioka S, Ohmoto K, Nakamura S, Kariyama K, Aikata H, Kobayashi Y, Tsutsui A.

Hepatol Res. 2012 Nov;42(11):1058-64. doi: 10.1111/j.1872-034X.2012.01025.x. Epub 2012 May 14.

PMID:
22583706
12.

Genetic screening for regulators of Prz1, a transcriptional factor acting downstream of calcineurin in fission yeast.

Koike A, Kato T, Sugiura R, Ma Y, Tabata Y, Ohmoto K, Sio SO, Kuno T.

J Biol Chem. 2012 Jun 1;287(23):19294-303. doi: 10.1074/jbc.M111.310615. Epub 2012 Apr 11.

13.

Anti-edematous effects of tolvaptan in experimental rodent models.

Miyazaki T, Sakamoto Y, Yamashita T, Ohmoto K, Fujiki H.

Cardiovasc Drugs Ther. 2011 Dec;25 Suppl 1:S77-82. doi: 10.1007/s10557-011-6355-z.

PMID:
22120096
14.

Chronic hyponatremia impairs memory in rats: effects of vasopressin antagonist tolvaptan.

Miyazaki T, Ohmoto K, Hirose T, Fujiki H.

J Endocrinol. 2010 Jul;206(1):105-11. doi: 10.1677/JOE-10-0050. Epub 2010 Apr 14.

PMID:
20392812
15.

Comparison of therapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas.

Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K, Kuboki M, Yamamoto S.

J Gastroenterol Hepatol. 2009 Feb;24(2):223-7. doi: 10.1111/j.1440-1746.2008.05596.x. Epub 2008 Sep 24.

PMID:
18823439
16.

[Pyogenic liver abscess complicated by gastric fistula and bacterial meningitis].

Tomiyama Y, Ohmoto K, Yoshioka N, Kawase T, Shibata N, Yoshida K, Kuboki M, Yamamoto S, Irei I, Urakami A, Tsunoda T.

Nihon Shokakibyo Gakkai Zasshi. 2007 Oct;104(10):1512-8. Review. Japanese.

PMID:
17917400
17.

Radiofrequency ablation versus percutaneous microwave coagulation therapy for small hepatocellular carcinomas: a retrospective comparative study.

Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K, Kuboki M, Yamamoto S.

Hepatogastroenterology. 2007 Jun;54(76):985-9.

PMID:
17629022
18.

[Hepatocellular carcinoma occurring after 11 year-long sustained viral response to interferon therapy for chronic hepatitis C].

Suganami F, Tomiyama Y, Ohmoto K, Kawase T, Yoshioka N, Shibata N, Yoshida K, Kuboki M, Yamamoto S.

Nihon Shokakibyo Gakkai Zasshi. 2007 Jun;104(6):809-14. Japanese.

PMID:
17548948
19.

Indole diterpene synthetic studies: development of a second-generation synthetic strategy for (+)-nodulisporic acids A and B.

Smith AB 3rd, Kürti L, Davulcu AH, Cho YS, Ohmoto K.

J Org Chem. 2007 Jun 22;72(13):4611-20. Epub 2007 May 19.

PMID:
17511508
20.

Indole diterpene synthetic studies. Total synthesis of (+)-nodulisporic acid F and construction of the heptacyclic cores of (+)-nodulisporic acids A and B and (-)-nodulisporic acid D.

Smith AB 3rd, Davulcu AH, Cho YS, Ohmoto K, Kürti L, Ishiyama H.

J Org Chem. 2007 Jun 22;72(13):4596-610. Epub 2007 May 19.

PMID:
17511507
21.

CO2-enhanced sonographically guided radiofrequency ablation and transcatheter arterial chemoembolization for small hepatocellular carcinoma poorly defined on conventional sonography.

Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K, Kuboki M, Yamamoto S.

J Clin Ultrasound. 2007 Feb;35(2):78-81.

PMID:
17195192
22.

Thermal ablation therapy for hepatocellular carcinoma: comparison between radiofrequency ablation and percutaneous microwave coagulation therapy.

Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K, Kuboki M, Yamamoto S.

Hepatogastroenterology. 2006 Sep-Oct;53(71):651-4.

PMID:
17086861
23.

Use of intra-arterial carbon-dioxide-enhanced ultrasonography for guidance of radiofrequency ablation and transcatheter arterial chemoembolization in hepatocellular carcinoma.

Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K, Kuboki M, Yamamoto S.

Cardiovasc Intervent Radiol. 2006 Nov-Dec;29(6):1111-3.

PMID:
16933161
24.

Comparison between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas.

Ohmoto K, Yamamoto S.

Clin Radiol. 2006 Sep;61(9):800-1; author reply 801-2. No abstract available.

PMID:
16905390
25.

Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis.

Ohmoto K, Yoshioka N, Yamamoto S.

J Gastroenterol. 2006 May;41(5):502-3. No abstract available.

PMID:
16799896
26.

Carbon dioxide-enhanced sonographically guided radiofrequency ablation plus transcatheter arterial chemoembolization for hepatocellular carcinoma.

Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K, Kuboki M, Yamamoto S.

J Vasc Interv Radiol. 2006 Apr;17(4):723-6.

PMID:
16614157
27.

Improved prognosis of cirrhosis patients with esophageal varices and thrombocytopenia treated by endoscopic variceal ligation plus partial splenic embolization.

Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Takesue M, Yoshida K, Kuboki M, Yamamoto S.

Dig Dis Sci. 2006 Feb;51(2):352-8.

PMID:
16534680
28.

Carbon dioxide-enhanced sonographically guided radiofrequency ablation combined with transcatheter arterial chemoembolization for sonographically undetectable hepatocellular carcinoma.

Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K, Kuboki M, Yamamoto S.

Hepatogastroenterology. 2005 Sep-Oct;52(65):1344-6.

PMID:
16201070
29.

Drug-induced megaloblastic anemia.

Iguchi Y, Ohmoto K, Wada H, Yamamoto S.

Dig Dis Sci. 2005 Oct;50(10):1778-9. No abstract available.

PMID:
16187172
30.

Treatment of multiple splenic aneurysms by coil embolization.

Ohmoto K, Yamamoto S.

AJR Am J Roentgenol. 2005 Aug;185(2):556-7; author reply 557. No abstract available.

PMID:
16037540
31.

Serum interleukin-6 and interleukin-10 in patients with acute pancreatitis: clinical implications.

Ohmoto K, Yamamoto S.

Hepatogastroenterology. 2005 Jul-Aug;52(64):990-4.

PMID:
16001614
32.

Combined intraarterial 5-fluorouracil and intramuscular interferon-alpha therapy for advanced hepatocellular carcinoma.

Ohmoto K, Iguchi Y, Mimura N, Tsuduki M, Shimabara M, Kuboki M, Yamamoto S.

Hepatogastroenterology. 2003 Nov-Dec;50(54):1780-2.

PMID:
14696403
33.
34.

Cryopreservation of primarily isolated porcine hepatocytes with UW solution.

Kunieda T, Maruyama M, Okitsu T, Shibata N, Takesue M, Totsugawa T, Kosaka Y, Arata T, Kobayashi K, Ikeda H, Oshita M, Nakaji S, Ohmoto K, Yamamoto S, Kurabayashi Y, Kodama M, Tanaka N, Kobayashi N.

Cell Transplant. 2003;12(6):607-16.

PMID:
14579929
35.

Maintenance of cold-preserved porcine hepatocyte function with UW solution and ascorbic acid-2 glucoside.

Takesue M, Maruyama M, Shibata N, Kunieda T, Okitsu T, Sakaguchi M, Totsugawa T, Kosaka Y, Arata A, Ikeda H, Matsuoka J, Oyama T, Kodama M, Ohmoto K, Yamamoto S, Kurabayashi Y, Yamamoto I, Tanaka N, Kobayashi N.

Cell Transplant. 2003;12(6):599-606.

PMID:
14579928
36.

Percutaneous microwave coagulation therapy for superficial hepatocellular carcinoma on the surface of the liver.

Ohmoto K, Mimura N, Iguchi Y, Mitsui Y, Shimabara M, Kuboki M, Yamamoto S.

Hepatogastroenterology. 2003 Sep-Oct;50(53):1547-51.

PMID:
14571783
37.

Combined lamivudine and interferon-alpha therapy for chemotherapy-induced reactivation of hepatitis B virus.

Ohmoto K, Tsuduki M, Yamamoto S.

Am J Gastroenterol. 2003 May;98(5):1215-6; author reply 1217. No abstract available.

PMID:
12809863
38.

Watermelon stomach: vascular ectasia may involve the cardia.

Ohmoto K, Mimura N, Yamamoto S.

Gastrointest Endosc. 2003 Apr;57(4):631. No abstract available.

PMID:
12665796
39.

Evaluation of toll-like receptor 4 gene expression of immortalized human liver cell lines.

Kobayashi N, Takesue M, Kobayashi N, Okitsu T, Matsumura T, Totsugawa T, Maruyama M, Morimoto Y, Kunieda T, Shibata N, Ohmoto K, Yamamoto S, Tanaka N.

Transplant Proc. 2003 Feb;35(1):431-2. No abstract available.

PMID:
12591474
40.

Drug-induced liver injury associated with antinuclear antibodies.

Ohmoto K, Yamamoto S.

Scand J Gastroenterol. 2002 Nov;37(11):1345-6. No abstract available.

PMID:
12465739
41.

Spontaneous regression of focal nodular hyperplasia of the liver.

Ohmoto K, Honda T, Hirokawa M, Mitsui Y, Iguchi Y, Kuboki M, Yamamoto S.

J Gastroenterol. 2002;37(10):849-53.

PMID:
12424570
42.

Transduction of immortalized human hepatocytes with p21 to enhance differentiated phenotypes.

Kunieda T, Kobayashi N, Sakaguchi M, Okitsu T, Totsugawa T, Watanabe T, Matsumura T, Maruyama M, Noguchi H, Takesue M, Shibata N, Ohmoto K, Fujiwara T, Yamamoto S, Tanaka N.

Cell Transplant. 2002;11(5):421-8.

PMID:
12382668
43.

CT-guided percutaneous ethanol injection therapy for ultrasonically invisible hepatocellular carcinoma.

Ohmoto K, Mimura N, Iguchi Y, Mitsui Y, Shimabara M, Kuboki M, Yamamoto S.

Hepatogastroenterology. 2002 Mar-Apr;49(44):297-9.

PMID:
11995437
44.

Nodulisporic acid A synthetic studies. 1. Overall strategy and construction of a western hemisphere subtarget.

Smith AB 3rd, Ishiyama H, Cho YS, Ohmoto K.

Org Lett. 2001 Nov 29;3(24):3967-70.

PMID:
11720581
45.

Effect of bezafibrate in primary biliary cirrhosis: a pilot study.

Ohmoto K, Mitsui Y, Yamamoto S.

Liver. 2001 Jun;21(3):223-4. No abstract available.

PMID:
11422787
46.

Design and synthesis of new orally active inhibitors of human neutrophil elastase.

Ohmoto K, Okuma M, Yamamoto T, Kijima H, Sekioka T, Kitagawa K, Yamamoto S, Tanaka K, Kawabata K, Sakata A, Imawaka H, Nakai H, Toda M.

Bioorg Med Chem. 2001 May;9(5):1307-23.

PMID:
11377188
47.

Percutaneous microwave coagulation therapy for superficial hepatocellular carcinoma using intraperitoneal infusion of local anesthetic.

Ohmoto K, Yamamoto S.

Am J Gastroenterol. 2001 May;96(5):1660-2. No abstract available.

PMID:
11374733
48.

Angioedema after interferon therapy for chronic hepatitis C.

Ohmoto K, Yamamoto S.

Am J Gastroenterol. 2001 Apr;96(4):1311-2. No abstract available.

PMID:
11316204
49.

Development of orally active nonpeptidic inhibitors of human neutrophil elastase.

Ohmoto K, Yamamoto T, Okuma M, Horiuchi T, Imanishi H, Odagaki Y, Kawabata K, Sekioka T, Hirota Y, Matsuoka S, Nakai H, Toda M, Cheronis JC, Spruce LW, Gyorkos A, Wieczorek M.

J Med Chem. 2001 Apr 12;44(8):1268-85.

PMID:
11312926
50.

The crystal structure of the complex of non-peptidic inhibitor of human neutrophil elastase ONO-6818 and porcine pancreatic elastase.

Odagaki Y, Ohmoto K, Matsuoka S, Hamanaka N, Nakai H, Toda M, Katsuya Y.

Bioorg Med Chem. 2001 Mar;9(3):647-51.

PMID:
11310599

Supplemental Content

Loading ...
Support Center